Insider activity noted: Social media chatter highlights a recent director sale of over a million dollars in shares near recent highs, sparking questions about timing amid the stock's sharp rally. Observers point to the company's strong cash position as a buffer against any near-term pressures.
Platform momentum discussed: Discussions emphasize the Atera instrument's sold-out status for the year, setting the stage for potential consumables growth in coming periods given the high-margin business model. Traders note the stock's climb from low single digits last year as evidence of renewed interest in single-cell analysis tools.
Valuation caution raised: Some voices flag instrument revenue softness as buyers await new systems, urging attention to moving averages after the multi-fold advance. Overall sentiment remains focused on execution in the spatial biology space without direct recommendations.
Note: This discussion summary was generated from an AI condensation of post data.
10x Genomics Insider Trading Activity
10x Genomics insiders have traded $TXG stock on the open market 31 times in the past 6 months. Of those trades, 0 have been purchases and 31 have been sales.
Here’s a breakdown of recent trading of $TXG stock by insiders over the last 6 months:
- ADAM TAICH (Chief Financial Officer) has made 0 purchases and 5 sales selling 78,652 shares for an estimated $4,446,341.
- SERGE SAXONOV (Chief Executive Officer) has made 0 purchases and 13 sales selling 107,924 shares for an estimated $3,990,693.
- JOHN R STUELPNAGEL has made 0 purchases and 5 sales selling 40,000 shares for an estimated $2,390,127.
- BENJAMIN J. HINDSON (See Remarks) has made 0 purchases and 2 sales selling 25,413 shares for an estimated $1,154,259.
- SARAH A. TEICHMANN has made 0 purchases and 2 sales selling 7,551 shares for an estimated $432,278.
- SHEHNAAZ SULIMAN has made 0 purchases and 4 sales selling 7,930 shares for an estimated $327,234.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
10x Genomics Revenue
10x Genomics had revenues of $151M in Q2 2026. This is a decrease of -12.65% from the same period in the prior year.
You can track TXG financials on Quiver Quantitative's TXG stock page.
You can access data on TXG stock through the Quiver Quantitative API.
10x Genomics Hedge Fund Activity
We have seen 200 institutional investors add shares of 10x Genomics stock to their portfolio, and 190 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PRICE T ROWE ASSOCIATES INC /MD/ added 4,375,792 shares (+2681.0%) to their portfolio in Q2 2026, for an estimated $167,767,865
- MILLENNIUM MANAGEMENT LLC removed 1,951,581 shares (-94.4%) from their portfolio in Q2 2026, for an estimated $74,823,615
- POINT72 ASSET MANAGEMENT, L.P. added 1,852,776 shares (+inf%) to their portfolio in Q2 2026, for an estimated $71,035,431
- ARK INVESTMENT MANAGEMENT LLC removed 1,714,260 shares (-14.6%) from their portfolio in Q2 2026, for an estimated $65,724,728
- WELLINGTON MANAGEMENT GROUP LLP removed 1,448,765 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $30,757,280
- CASDIN CAPITAL, LLC removed 1,225,000 shares (-53.8%) from their portfolio in Q2 2026, for an estimated $46,966,500
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 1,087,150 shares (+inf%) to their portfolio in Q2 2026, for an estimated $41,681,331
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
10x Genomics Government Contracts
We have seen $5,298,707 of award payments to $TXG over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- PROSTHETIST, PROSTHETIST TECHNICIAN, AND PROSTHETIST ASSISTANT IN THE DEPARTMENT OF SURGICAL SERVICES AND R...: $371,793
- BIOLOGICAL REAGENT MATERIAL - CHROMIUM NEXT GEM SINGLE CELL MULTIOME AND GEM-X SINGLE CELL 5 KITS AND RELAT...: $249,991
- REAGENTS FOR ONGOING NGS PROJECTS (AMBIS 2270566): $249,963
- IN-VITRO DIAGNOSTIC SUBSTANCE MANUFACTURING - GEM-X UNIVERSAL GENE EXPRESSION AND CHROMIUM GEM-X SINGLE CEL...: $249,785
- IN-VITRO DIAGNOSTIC SUBSTANCE MANUFACTURING - GEM-X UNIVERSAL GENE EXPRESSION AND GEM-X SINGLE CELL CHIP KITS: $246,534
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.
10x Genomics Analyst Ratings
Wall Street analysts have issued reports on $TXG in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- William Blair issued a "Outperform" rating on 03/31/2026
To track analyst ratings and price targets for 10x Genomics, check out Quiver Quantitative's $TXG forecast page.
10x Genomics Price Targets
Multiple analysts have issued price targets for $TXG recently. We have seen 8 analysts offer price targets for $TXG in the last 6 months, with a median target of $38.5.
Here are some recent targets:
- Tejas Savant from Morgan Stanley set a target price of $37.0 on 07/09/2026
- Patrick Donnelly from Citigroup set a target price of $45.0 on 07/08/2026
- Eric Winmill from Scotiabank set a target price of $100.0 on 07/08/2026
- David Westenberg from Piper Sandler set a target price of $42.0 on 07/01/2026
- Luke Sergott from Barclays set a target price of $40.0 on 06/24/2026
- Casey Woodring from JP Morgan set a target price of $20.0 on 05/12/2026
- Kyle Mikson from Canaccord Genuity set a target price of $32.0 on 04/20/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
